Cancer mortality predictions for 2019 in Latin America

Carioli, Greta; Bertuccio, Paola; Malvezzi, Matteo; Rodrı́guez, Teresa; Levi, Fabio; Boffetta, Paolo; Vecchia, Carlo La; Negri, Eva

doi:10.1002/ijc.32749

Cited by 48 publications

(47 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Analysis included deaths due to leukemia (C91-C95) according to the International Statistical Classi cation of Diseases and Related Health Problems -10 th revision (ICD10) (16). Population data by country, sex, and age were obtained from the Pan American Health Organization (17) similar to previous studies in Latin America (18,19).…”

Section: Design and Study Settingmentioning

confidence: 99%

Leukemia mortality in children from Latin America: Trends and predictions to 2030

Torres-Román

Valcárcel

Guerra-Canchari

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Reports suggest that Latin American and Caribbean (LAC) countries have not achieved the downward mortality trends in leukemia seen in other countries. However, updated trends remain largely unknown in the region. Given that leukemia is the leading cause of cancer-related death in LAC children, we aimed to evaluate mortality trends in children (0-14y) from 15 LAC countries for the period 2000–2017 and to predict mortality until 2030. Methods We retrieved cancer mortality data through the World Health Organization Mortality Database. Age-standardized (world standard population) rates were computed for LAC countries. Joinpoint regression analysis was used to examine trends in the mortality rates of leukemia and provide an estimated annual percent change (EAPC). Nordpred was utilized for the calculation of predictions until 2030. Results Between 2013 and 2017, the highest mortality rates were reported in Venezuela, Ecuador, Nicaragua, Mexico, and Peru. Upward mortality trends were reported in Nicaragua (EAPC by 1.2% in boys, and EAPC by 2.0% in girls), Panama (EAPC by 1.8% in boys, and by 2.7% in girls), and Peru (EAPC by 1.4% in both sexes). Puerto Rico experienced large declines in mortality among both boys (APC by − 9.7%), and girls (EAPC by − 6.0%). Forecasting models predicted that leukemia mortality between 2015 and 2030, will increase in Argentina, Ecuador, Guatemala, Panama, Peru, and Uruguay. Conclusion Leukemia mortality is predicted to increase unless efforts are made to intervene. Interventions include addressing the inequities in health care diagnosing cases earlier,, avoiding treatment abandonment, and proper supportive care such as infection control programs will reduce the mortality in a great proportion.

show abstract

Section: Design and Study Settingmentioning

confidence: 99%

Leukemia mortality in children from Latin America: Trends and predictions to 2030

Torres-Román

Valcárcel

Guerra-Canchari

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…In total, 62,100 new urinary bladder cancer cases and 13,050 deaths are estimated to the United States in 2020 (Siegel et al ., 2020). Between 1990 and 2019, no decline was observed at urinary bladder cancer mortality rates in Brazil and Cuba (Carioli et al ., 2019). Usually deaths caused by this type of tumor occur in less developed countries, due to a lack of structure to assist the patients in detection (Siegel et al ., 2017).…”

Section: Introductionmentioning

confidence: 99%

Inhibition of urinary bladder cancer cell proliferation by silibinin

Barros

Lima

Almeida

et al. 2020

Environ and Mol Mutagen

View full text Add to dashboard Cite

Silibinin, a natural compound extracted from milk thistle, has demonstrated antitumor properties in urinary bladder cancer cells; however, the role of TP53 gene in these effects is unclear. In order to better understand the molecular and antiproliferative mechanisms of this compound, urinary bladder cancer cells with different TP53 gene status, RT4 (low-grade tumor, wild TP53 gene), 5637 (high-grade tumor, Grade 2, mutated TP53 gene), and T24 (high-grade tumor, Grade 3, mutated TP53 gene) were treated with several concentrations of silibinin (1, 5, 10, 50, 100, and 150 μM). Cytotoxicity, prooxidant effect, morphological changes, cell migration, cell cycle progression, global methylation profile, and relative expression of HOXB3, c-MYC, PLK1, SMAD4, SRC, HAT, HDAC, and RASSF1A genes were evaluated. The silibinin presented cytotoxic and prooxidant effects in the three cell lines. In mutated TP53 cells, significant interference in cell migration and cell cycle arrest at the G2/M phase was observed. Additionally, silibinin induced global DNA hypomethylation in the highest grade tumor cells. For wild-type TP53 cells, a sub-G1 apoptotic population was present. Furthermore, there was modulation of gene expression responsible for cell growth (SMAD and c-MYC), migration (SRC), cell cycle kinetics (PLK1), angiogenesis (HOXB3), and of genes associated with epigenetic events such as DNA acetylation (HAT) and deacetylation (HDAC).In conclusion, the silibinin inhibited the urinary bladder tumor cell proliferation independently of TP53 status; however, cell cycle effects, gene expression changes, and alteration of cell migration are dependent on TP53 status.

show abstract

“…Regarding mortality, its distribution varied widely between regions, being the Eastern region the one that had lower ASR than national for all types of cancer. According to previous studies, disparities in mortality can be explained by diagnosis in advanced stages, limited access to quality health services and treatment opportunity (16)(17)(18). However, in our study population, there were no differences between the proportion of people diagnosed with invasive neoplasms or the rst treatment initiation.…”

Section: Discussionmentioning

confidence: 99%

Patterns of breast, prostate and cervical cancer incidence and mortality in Colombia: An administrative registry data analysis

Vargas¹,

Barbosa²,

Quijano³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Cancer is widely recognized as a global public health problem. Breast, prostate and cervical cancer are among the most frequent types in developing countries. Assessing their incidence and mortality by regions and municipalities is important to guide evidence-based health policy. Our aim was to describe the incidence and mortality trends for breast, cervical and prostate cancer across regions and municipalities in Colombia during 2018. Methods We performed a cross-sectional analysis with data from people with breast, prostate or cervical cancer, reported to the National Administrative Cancer Registry during 2018. A descriptive analysis was performed. Age-standardized incidence and mortality rates were estimated at national, regional and municipal levels. Finally, we identify the regions and municipalities with significantly higher or lower incidence and mortality rates compared to national estimations. Results Breast cancer was the most frequent type among all new cases and deaths in Colombia. Breast, prostate and cervical cancer incidence and mortality rates were: 18,69 (CI 95%: 18,15–19,25) and 10,48 (CI 95%: 10,07–10,91); 11,34 (CI 95%: 10,90 − 11,78) and 7,58 (CI 95%: 7,22 − 7,96); 5,93 (CI 95%: 5,62 − 6,25) and 4,31 (CI 95%: 4,05 − 4,58), respectively. Eastern region had both, incidence and mortality rates, significantly lower than national for all types of cancer. By municipalities, there were a heterogeneous pattern. Nonetheless, Agua de Dios (Cundinamarca), had one of the highest incidence rates for all types. Conclusions We observed clear differences in cancer incidence and mortality across regions and municipalities, depending on each type of cancer. Our findings are important to improve screening coverage, early detection and treatment in the country.

show abstract

Cancer mortality predictions for 2019 in Latin America

Cited by 48 publications

References 43 publications

Leukemia mortality in children from Latin America: Trends and predictions to 2030

Leukemia mortality in children from Latin America: Trends and predictions to 2030

Inhibition of urinary bladder cancer cell proliferation by silibinin

Patterns of breast, prostate and cervical cancer incidence and mortality in Colombia: An administrative registry data analysis

Contact Info

Product

Resources

About